D. E. Shaw & Co. Inc. Lowers Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

D. E. Shaw & Co. Inc. trimmed its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 56.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 82,578 shares of the company’s stock after selling 105,619 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.13% of Kymera Therapeutics worth $3,322,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of KYMR. Franklin Resources Inc. boosted its holdings in Kymera Therapeutics by 35.1% during the 3rd quarter. Franklin Resources Inc. now owns 29,440 shares of the company’s stock valued at $1,356,000 after acquiring an additional 7,647 shares during the period. Blue Trust Inc. boosted its holdings in Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after acquiring an additional 270 shares during the period. KBC Group NV boosted its holdings in Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after acquiring an additional 752 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Kymera Therapeutics by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,733 shares of the company’s stock valued at $552,000 after acquiring an additional 1,311 shares during the period. Finally, Rhumbline Advisers boosted its holdings in Kymera Therapeutics by 3.0% during the 4th quarter. Rhumbline Advisers now owns 64,157 shares of the company’s stock valued at $2,581,000 after acquiring an additional 1,861 shares during the period.

Insider Buying and Selling

In related news, COO Jeremy G. Chadwick sold 1,383 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the transaction, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. This trade represents a 2.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. This represents a 3.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,659 shares of company stock worth $324,567 in the last quarter. 16.01% of the stock is owned by insiders.

Analysts Set New Price Targets

KYMR has been the subject of a number of research analyst reports. UBS Group lowered their target price on Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. Guggenheim reaffirmed a “buy” rating and issued a $52.00 price target on shares of Kymera Therapeutics in a research report on Monday, May 12th. Citigroup assumed coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They issued a “buy” rating and a $52.00 price target on the stock. Stephens reaffirmed an “overweight” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Finally, Bank of America reduced their price target on Kymera Therapeutics from $47.00 to $44.00 and set a “neutral” rating on the stock in a research report on Monday, May 12th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $55.27.

Kymera Therapeutics Stock Performance

Shares of NASDAQ KYMR opened at $30.25 on Monday. Kymera Therapeutics, Inc. has a fifty-two week low of $19.45 and a fifty-two week high of $53.27. The firm has a market capitalization of $1.97 billion, a PE ratio of -12.93 and a beta of 2.18. The stock’s 50-day simple moving average is $29.36 and its 200-day simple moving average is $36.92.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.10. The firm had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm’s quarterly revenue was up 114.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.69) EPS. On average, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.